Clinical Trial Update: Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the protective efficacy of a vaccine derived from the synthetic circumsporozoite protein of Plasmodium vivax has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Synthetic CS protein vaccine (Plasmodium vivax)

Snippet

Sponsor: Malaria Vaccine and Drug Development Center | Conditions: Malaria | Phase 2 | Status: COMPLETED